Blockchain Registration Transaction Record

Biotech Leader Philip Ashton-Rickardt on When to Pivot in Science

Philip Ashton-Rickardt, CSO at BE Therapeutics, shares insights on scientific leadership, pivoting in biotech, and the importance of curiosity and transparency.

In an era of rapid scientific advancement, knowing when to abandon a hypothesis is as critical as knowing when to pursue one. Ashton-Rickardt's emphasis on separating attachment to ideas from attachment to problems can prevent costly delays in drug development, where rigid thinking often leads to dead ends. His call for transparent leadership—acknowledging uncertainty rather than feigning omniscience—builds trust and encourages teams to speak up, which is vital for innovation. As biotech companies race to develop therapies for neurological diseases and cancer, the ability to pivot based on evidence can mean the difference between breakthrough and failure. Ultimately, this approach not only accelerates progress but also fosters a healthier scientific culture that prioritizes solving problems over protecting egos.